179 related articles for article (PubMed ID: 31882719)
1. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
Kuroki H; Anraku T; Kazama A; Bilim V; Tasaki M; Schmitt D; Mazar AP; Giles FJ; Ugolkov A; Tomita Y
Sci Rep; 2019 Dec; 9(1):19977. PubMed ID: 31882719
[TBL] [Abstract][Full Text] [Related]
2. GSK-3 inhibition overcomes chemoresistance in human breast cancer.
Ugolkov A; Gaisina I; Zhang JS; Billadeau DD; White K; Kozikowski A; Jain S; Cristofanilli M; Giles F; O'Halloran T; Cryns VL; Mazar AP
Cancer Lett; 2016 Oct; 380(2):384-392. PubMed ID: 27424289
[TBL] [Abstract][Full Text] [Related]
3. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP
Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250
[TBL] [Abstract][Full Text] [Related]
4. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
Anraku T; Kuroki H; Kazama A; Bilim V; Tasaki M; Schmitt D; Mazar A; Giles FJ; Ugolkov A; Tomita Y
Int J Mol Med; 2020 Feb; 45(2):315-323. PubMed ID: 31894292
[TBL] [Abstract][Full Text] [Related]
6. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
Pal K; Cao Y; Gaisina IN; Bhattacharya S; Dutta SK; Wang E; Gunosewoyo H; Kozikowski AP; Billadeau DD; Mukhopadhyay D
Mol Cancer Ther; 2014 Feb; 13(2):285-96. PubMed ID: 24327518
[TBL] [Abstract][Full Text] [Related]
8. Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells.
Shirono Y; Bilim V; Anraku T; Kuroki H; Kazama A; Murata M; Hiruma K; Tomita Y
Curr Oncol; 2023 May; 30(6):5350-5365. PubMed ID: 37366889
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
[TBL] [Abstract][Full Text] [Related]
10. Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer.
Chen S; Sun KX; Feng MX; Sang XB; Liu BL; Zhao Y
Drug Des Devel Ther; 2016; 10():1225-32. PubMed ID: 27051274
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Glycogen Synthase Kinase 3β Increases the Proportion and Suppressive Function of CD19
Li J; Gao J; Zhou H; Zhou J; Deng Z; Lu Y; Rao J; Ji G; Gu J; Yang X; Xia Y; Wang X
Front Immunol; 2020; 11():603288. PubMed ID: 33343576
[TBL] [Abstract][Full Text] [Related]
12. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β.
Gerhardt D; Bertola G; Dietrich F; Figueiró F; Zanotto-Filho A; Moreira Fonseca JC; Morrone FB; Barrios CH; Battastini AM; Salbego CG
Urol Oncol; 2014 Jan; 32(1):36.e1-9. PubMed ID: 24239461
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
14. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β.
Yang Z; Liu H; Pan B; He F; Pan Z
Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013
[TBL] [Abstract][Full Text] [Related]
16. Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Jeffers A; Qin W; Owens S; Koenig KB; Komatsu S; Giles FJ; Schmitt DM; Idell S; Tucker TA
Sci Rep; 2019 Dec; 9(1):18925. PubMed ID: 31831767
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
Yoon AR; Jiao A; Hong J; Kim B; Yun CO
Front Immunol; 2024; 15():1360436. PubMed ID: 38812516
[TBL] [Abstract][Full Text] [Related]
19. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.
Xiong Q; Liu A; Ren Q; Xue Y; Yu X; Ying Y; Gao H; Tan H; Zhang Z; Li W; Zeng S; Xu C
Cell Death Dis; 2020 May; 11(5):366. PubMed ID: 32409654
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
Hsu A; Huntington KE; De Souza A; Zhou L; Olszewski AJ; Makwana NP; Treaba DO; Cavalcante L; Giles FJ; Safran H; El-Deiry WS; Carneiro BA
Cancer Biol Ther; 2022 Dec; 23(1):417-423. PubMed ID: 35815408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
